派姆单抗治疗头颈部鳞状细胞癌:临床病例和现实世界的实践

Yu. V. Alymov, I. S. Romanov, A. V. Ignatova
{"title":"派姆单抗治疗头颈部鳞状细胞癌:临床病例和现实世界的实践","authors":"Yu. V. Alymov, I. S. Romanov, A. V. Ignatova","doi":"10.17650/2222-1468-2023-13-2-35-43","DOIUrl":null,"url":null,"abstract":"Recurrent and metastatic head and neck squamous cell carcinoma is a hard-to-treat pathology. median overall survival for standard chemotherapy regimens does not exceed 11 months. One of the factors decreasing treatment effectivenessis frequency of severe adverse events which are observed in every 2nd patient during standard therapy regimens. moreover, even if notable tumor regression is achieved, this effect is transient. Development of immunotherapy drugs, namely pembrolizumab, helps solve these problems. Clinical trials and real-world use of the drug show that in the 1st and 2nd therapy lines for recurrent and metastatic head and neck squamous cell carcinoma, pembrolizumab allows to achieve persistent treatment response, increase overall survival, and decrease the frequency of adverse events.","PeriodicalId":19610,"journal":{"name":"Opuholi Golovy i Šei","volume":"41 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pembrolizumab in treatment of head and neck squamous cell carcinoma: clinical cases and real-world practice\",\"authors\":\"Yu. V. Alymov, I. S. Romanov, A. V. Ignatova\",\"doi\":\"10.17650/2222-1468-2023-13-2-35-43\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Recurrent and metastatic head and neck squamous cell carcinoma is a hard-to-treat pathology. median overall survival for standard chemotherapy regimens does not exceed 11 months. One of the factors decreasing treatment effectivenessis frequency of severe adverse events which are observed in every 2nd patient during standard therapy regimens. moreover, even if notable tumor regression is achieved, this effect is transient. Development of immunotherapy drugs, namely pembrolizumab, helps solve these problems. Clinical trials and real-world use of the drug show that in the 1st and 2nd therapy lines for recurrent and metastatic head and neck squamous cell carcinoma, pembrolizumab allows to achieve persistent treatment response, increase overall survival, and decrease the frequency of adverse events.\",\"PeriodicalId\":19610,\"journal\":{\"name\":\"Opuholi Golovy i Šei\",\"volume\":\"41 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Opuholi Golovy i Šei\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17650/2222-1468-2023-13-2-35-43\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Opuholi Golovy i Šei","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17650/2222-1468-2023-13-2-35-43","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

复发性和转移性头颈部鳞状细胞癌是一种难以治疗的病理。标准化疗方案的中位总生存期不超过11个月。降低治疗效果的因素之一是严重不良事件的发生频率,在标准治疗方案中每2例患者中就有1例出现严重不良事件。此外,即使实现了显著的肿瘤消退,这种效果也是短暂的。免疫治疗药物的开发,即派姆单抗,有助于解决这些问题。临床试验和该药物的实际使用表明,在复发和转移性头颈部鳞状细胞癌的第一和第二治疗线中,派姆单抗可以实现持续的治疗反应,增加总生存期,并降低不良事件的频率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Pembrolizumab in treatment of head and neck squamous cell carcinoma: clinical cases and real-world practice
Recurrent and metastatic head and neck squamous cell carcinoma is a hard-to-treat pathology. median overall survival for standard chemotherapy regimens does not exceed 11 months. One of the factors decreasing treatment effectivenessis frequency of severe adverse events which are observed in every 2nd patient during standard therapy regimens. moreover, even if notable tumor regression is achieved, this effect is transient. Development of immunotherapy drugs, namely pembrolizumab, helps solve these problems. Clinical trials and real-world use of the drug show that in the 1st and 2nd therapy lines for recurrent and metastatic head and neck squamous cell carcinoma, pembrolizumab allows to achieve persistent treatment response, increase overall survival, and decrease the frequency of adverse events.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信